EMA's CHMP is going to perform an accelerated assessment of data submitted by Moderna regarding the use of a booster dose of Spikevax.
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) is going to perform an accelerated assessment of data submitted by Moderna regarding the use of a booster dose of Spikevax (the company’s COVID-19 vaccine).
According to a Sep. 27, 2021 press release, Moderna has applied to the regulatory authority for the use of a booster dose of Spikevax to be given at least six months after the second dose of the vaccine in people 12 years old and older. Based on its review of available data, CHMP will recommend whether or not updates to the product information are appropriate.
In a separate communication, EMA and the European Centre for Disease Prevention and Control (ECDC) have specified that the need for additional and booster doses of COVID-19 vaccines is not urgent for the general population. However, Moderna’s application is being considered to ensure evidence is available to support further doses as necessary.
Source: EMA
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.